Importantly, trastuzumab deruxtecan is the only ADC used to treat HER2-mutated NSCLC, signifying an innovative approach to using ADCs in targeted therapy for NSCLC (10). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.